

Interferon - Biosimilar Insight, 2022

<https://marketpublishers.com/r/I8E22DC15D76EN.html>

Date: January 2022

Pages: 70

Price: US\$ 1,000.00 (Single User License)

ID: I8E22DC15D76EN

Abstracts

This report can be delivered to the clients within 48-72 hours

DelveInsight's, "Interferon– Biosimilar 2022," report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Interferon Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Interferon Understanding

Interferon: Overview

Interferons are a group of signaling proteins made and released by host cells in response to the presence of several viruses. In a typical scenario, a virus-infected cell will release interferons causing nearby cells to heighten their anti-viral defenses. Interferon is further categorized in its variants.

Interferon alfa-2b is an antiviral or antineoplastic drug. It is a recombinant form of the protein Interferon alpha-2 that was originally sequenced and produced recombinantly in *E. coli* in the laboratory of Charles Weissmann at the University of Zurich, in 1980.

Interferon beta-1a is a cytokine in the interferon family used to treat multiple sclerosis. It

is produced by mammalian cells, while interferon beta-1b is produced in modified E. coli. Some claims have been made that Interferons produce about an 18–38% reduction in the rate of MS relapses.

Interferon Biosimilars: Drugs Chapters

This segment of the Interferon report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interferon Biosimilars: Marketed Drugs

Bioferon: Biosidus

Bioferon is being developed by Biosidus. The drug is being approved for the treatment of Cancer; Hepatitis B; Hepatitis C; Kaposi's sarcoma.

Further product details are provided in the report.....

Interferon Biosimilars: Emerging Drugs

Interferon beta-1b biosimilar: Harvest Moon Pharmaceuticals

Harvest Moon Pharmaceuticals is developing Interferon beta-1b biosimilar for the treatment of Multiple sclerosis.

Further product details are provided in the report.....

Interferon: Therapeutic Assessment

This segment of the report provides insights about the different Interferon biosimilars segregated based on following parameters that define the scope of the report, such as:

Major Players in Interferon

There are approx. 10+ key companies which are developing the therapies for Interferon.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Marketed stage products

Late stage products (BLA Filed and Phase III)

Mid-stage products (Phase II and

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Interferon pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibodies

Peptide

Protein

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interferon: Pipeline Development Activities

The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Interferon biosimilars drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interferon biosimilar drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Interferon R&D. The therapies under development are focused on novel approaches to treat/improve Interferon.

Interferon Biosimilars Report Insights

Interferon Biosimilar Pipeline Analysis

Therapeutic Assessment

Sales Assessment

Unmet Needs

Impact of Drugs

Interferon Biosimilar Report Assessment

Marketed Product profiles

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Sales Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Interferon Biosimilars?

How many Interferon biosimilars are developed by each company?

How many emerging biosimilars are in mid-stage, and late-stage?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interferon biosimilars therapeutics?

What are the clinical studies going on for Interferon biosimilars and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Zydus Cadila

Reliance Life Sciences

Profarma

Harvest Moon Pharmaceuticals

Dong-A ST

CinnaGen

BioPartners

Biocad

Amega Biotech

Key Products

MAB 2

ReliBeta

PF-08

Interferon beta-1b biosimilar

DA-3051

Cinno Vex

ReciGen

Bioferon

Inmutag

Alpheon

BCD-033

Megavex

Contents

1. KEY INSIGHTS

2. INTERFERON BIOSIMILARS: SNAPSHOT

3. EXECUTIVE SUMMARY

3.1. Overview

3.2. The Basics of Biologics.

3.3. Biosimilars are not the Same as Generic Drugs

3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?

3.5. What Patients Need to Know About Biosimilars

4. REGULATORY OUTLOOK FOR BIOSIMILARS

4.1. North America

4.1.1. US

4.1.2. Canada

4.2. Europe

4.3. Asia Pacific

4.3.1. China

4.3.2. India

4.3.3. Japan

4.3.4. South Korea

4.3.5. Australia

4.4. Rest Of The World

4.4.1. Brazil

4.4.2. Mexico

4.4.3. Argentina

4.4.4. Saudi Arabia

*More Countries would be added in the final report

5. INTERFERON (REFERENCE PRODUCT: AVONEX)

5.1. Drug Profile

5.2. Product Overview

5.3. Regulatory Approvals and Launch

5.4. Indications

- 5.5. Mechanism of Action
- 5.6. Dosage and Administration
- 5.7. Dosage and Strengths
- 5.8. Dose Modification
- 5.9. Route of Synthesis
- 5.10. Pharmacology
- 5.11. Pharmacodynamics
- 5.12. Pharmacokinetics
- 5.13. Adverse Reactions
- 5.14. Product Snapshot
- 5.15. Development Milestones

6. RESEARCH AND DEVELOPMENT

- 6.1. Clinical Trials Information
- 6.2. Safety and Efficacy

7. AVONEX BIOSIMILAR: EMERGING OPPORTUNITIES

*More variants of Interferon would be added in the final report

8. INTERFERON: BIOSIMILARS ASSESSMENT

- 8.1. Assessment by Product Type
- 8.2. Assessment by Route of Administration
- 8.3. Assessment by Molecule type
- 8.4. Sales Assessment

9. INTERFERON BIOSIMILARS PROFILES: BY COMPANY

- 9.1.1. Zydus Cadila
 - 9.1.1.1. MAB 2: Zydus Cadila
 - 9.1.1.1.1. Product Information
 - 9.1.1.1.2. Research and Development
 - 9.1.1.1.3. Other Development Activities
 - 9.1.1.1.4. General Description Table
- 9.1.2. Profarma
 - 9.1.2.1. PF-08: Profarma
 - 9.1.2.1.1. Product Information

9.1.2.1.2. Research and Development

9.1.2.1.3. Other Development Activities

9.1.2.1.4. General Description Table

*More Companies and products would be added in the final report

10. INTERFERON BIOSIMILARS: COMPARATIVE LANDSCAPE: BY COMPANY

11. INTERFERON BIOSIMILARS: COMPETITIVE LANDSCAPE

11.1.1. Overview

11.1.2. Market Share Analysis

11.1.3. Competitive Scenario

11.1.3.1. Product Launches and approval

11.1.3.2. Partnerships, Collaborations and Agreements

11.1.3.3. Acquisitions

11.1.3.4. Expansions

11.1.3.5. Patent Expiration of Biologics

*More information would be added in the final report

12. MARKET DRIVERS

13. MARKET BARRIERS

14. SWOT ANALYSIS

15. APPENDIX

15.1. Research Methodology

15.1.1. Coverage

15.1.2. Secondary Research

16. BIBLIOGRAPHY

17. DELVEINSIGHT CAPABILITIES

18. DISCLAIMER

19. ABOUT DELVEINSIGHT

I would like to order

Product name: Interferon - Biosimilar Insight, 2022

Product link: <https://marketpublishers.com/r/l8E22DC15D76EN.html>

Price: US\$ 1,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l8E22DC15D76EN.html>